LIPFENDRA is Merck's brand name for [[enlicitide]], the first FDA-approved oral PCSK9 inhibitor. The molecule is a novel macrocyclic peptide engineered to survive gastrointestinal enzymes and be absorbed intact through the intestinal wall, unlike the linear peptides and monoclonal antibodies that populate the injectable-drug catalog.
The FDA approved LIPFENDRA 20 mg tablets on July 16, 2026 as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The registrational Phase 3 CORALreef program delivered 56% placebo-adjusted LDL-C reduction in CORALreef Lipids and 59% in CORALreef HeFH, matching the efficacy of injectable PCSK9 monoclonal antibodies (Amgen Repatha, Regeneron/Sanofi Praluent). Head-to-head add-on data showed LIPFENDRA outperformed Nexletol (bempedoic acid) and Zetia (ezetimibe) on LDL reduction.
Commercial launch details: $10.50 per tablet, or $315 per 30-day supply list price, roughly one-third the injectable-class prices. Distributed through standard retail and mail-order pharmacies under the pharmacy benefit (Novartis Leqvio, by contrast, runs through the medical benefit). Analysts model $2 billion or more in peak annual sales. The CORALreef Outcomes cardiovascular trial (NCT06008756) has completed enrollment with more than 14,500 participants, with results expected in 2028-2029.
Stories here cover LIPFENDRA clinical readouts, commercial launch, payer coverage, and the oral-peptide-versus-injectable-antibody positioning. See [[enlicitide]], [[pcsk9-inhibitor]], [[macrocyclic-peptide]], and [[merck]] for adjacent threads.
The peptide-and-obesity Q2 2026 earnings week (Merck August 4, Pfizer August 4, Amgen August 4, Eli Lilly August 5, Novo Nordisk H1 August 4-5) delivered mixed signals across the pharma sector. Merck (NYSE: MRK) posted $16.61 billion Q2 revenue (+5% YoY, beat consensus by $250M), raised FY revenue guidance to $66.3-67.3 billion but cut adjusted EPS guidance to $2.66-2.76 due to a $5.7 billion Terns Pharmaceuticals acquisition charge; Keytruda reached $8.37 billion (+5%) and LIPFENDRA (enlicitide) launched at $315/month with $5 billion peak sales potential by 2034. Pfizer (NYSE: PFE) reported $15 billion revenue and $0.77 adjusted diluted EPS, raised FY revenue guidance midpoint to $60.5-62.5 billion, and CEO Bourla said the obesity program (danuglipron plus Metsera pipeline) is advancing with substantial momentum. Amgen (NASDAQ: AMGN) reported $10.05 billion Q2 revenue (+10% YoY), raised FY guidance to $38.2-39.4 billion, discontinued AMG 513 early-stage obesity candidate leaving MariTide as sole obesity focus. Eli Lilly (NYSE: LLY) delivered $23 billion Q2 revenue (+48% YoY blowout), raised FY guidance to $85-87 billion, Mounjaro reached $9.9 billion (+91%), Zepbound $4.9 billion US (+44%), and Foundayo generated $98 million in first fully operational commercial quarter. Novo Nordisk H1 reached 78.49 billion DKK ($12.09 billion, +3% CER) with Wegovy pill at 5 million+ prescriptions and raised guidance; NVO shares fell 5% on margin concerns. Alnylam (NASDAQ: ALNY) extended a 30% selloff (approximately $12 billion market cap lost) since the July 30 Q2 report on the Amvuttra TTR guidance cut plus eplontersen setback.
Merck (NYSE: MRK) reported Q2 2026 earnings Tuesday August 4, 2026 before market open with quarterly revenue of $16.61 billion (+5% year-over-year), beating analyst consensus of $16.36 billion. Keytruda (pembrolizumab) generated $8.37 billion in Q2 sales (+5% YoY), exceeding analyst expectations of $8.27 billion; the total includes $463 million from the newly-launched more convenient injectable Keytruda formulation. Merck highlighted the July 16, 2026 LIPFENDRA (enlicitide) FDA approval as the first once-daily oral macrocyclic peptide PCSK9 inhibitor in the class, priced at $315 per month with peak sales potential of $5 billion by 2034. Full-year 2026 revenue guidance was raised to $66.3-67.3 billion from the prior $65.8-67 billion range, but adjusted EPS guidance was cut to $2.66-2.76 to reflect a one-time $5.7 billion ($2.31 per share) charge tied to the Terns Pharmaceuticals acquisition that closed in H1 2026. Merck shares rose 0.6% in early trading to $128.54. Broader pipeline highlights include continued growth of Winrevair (sotatercept for pulmonary arterial hypertension), Welireg (belzutifan for renal cell carcinoma), and Capvaxive (pneumococcal vaccine), plus the integration of Terns and Cidara acquisitions. Merck has beaten consensus in each of the trailing four quarters.
Merck (NYSE: MRK) Q2 2026 earnings pre-day positioning ahead of the Tuesday August 4, 2026 before-market-open report. Zacks analyst consensus: $16.33 billion revenue, $1.36 diluted EPS (down 36.2% year-over-year from $2.13 in Q2 2025). Analyst focus areas: Keytruda (pembrolizumab) sales trajectory (Zacks estimate $8.06 billion Q2, driven by earlier-stage indication uptake and continued metastatic-setting momentum) ahead of the 2028 US patent cliff that ends Keytruda exclusivity; the initial commercial ramp of LIPFENDRA (enlicitide) oral macrocyclic peptide PCSK9 inhibitor following the July 16, 2026 FDA approval, with peak sales potential estimated at $5 billion by 2034 and analyst commentary describing the safety label as 'the cleanest in the class'; contribution from Winrevair (sotatercept for pulmonary arterial hypertension), Welireg (belzutifan for renal cell carcinoma), and Capvaxive (pneumococcal vaccine); and the integration of the Terns Pharmaceuticals and Cidara Therapeutics acquisitions closed in H1 2026. Merck has beaten earnings expectations in each of the trailing four quarters with a 7.75% average earnings surprise; analyst attention also on potential FY 2026 revenue guidance revision from the prior $65.8-67 billion range and non-GAAP EPS guidance from $5.04-5.16.
Merck (NYSE: MRK) reports Q2 2026 earnings Tuesday August 4, 2026 before market open with Zacks analyst consensus at $16.33 billion revenue and $1.36 diluted EPS (-36.2% year-over-year from $2.13 in Q2 2025). Analyst focus areas: Keytruda (pembrolizumab) sales trajectory with the Zacks estimate at $8.06 billion Q2, driven by earlier-stage indication uptake and continued metastatic-setting momentum ahead of the 2028 US patent cliff; the initial commercial launch of LIPFENDRA (enlicitide) macrocyclic peptide oral PCSK9 inhibitor following the July 16, 2026 FDA approval at $315/month list price ($10.50 per tablet), with peak sales potential estimated at $5 billion by 2034; the emerging contribution of Winrevair (sotatercept for pulmonary arterial hypertension), Welireg (belzutifan for renal cell carcinoma and VHL disease), and Capvaxive (pneumococcal vaccine); and pipeline signal from the Terns Pharmaceuticals and Cidara Therapeutics acquisitions completed in H1 2026. Merck has beaten earnings expectations in each of the trailing four quarters with a 7.75% average earnings surprise. Beyond Q2 specifically, analyst attention will focus on the FY 2026 revenue guidance ($65.8-67 billion range on the prior call) and non-GAAP EPS guidance ($5.04-5.16 range) for revisions.
Q2 2026 earnings from the peptide-and-obesity big three arrive next week. Merck (NYSE: MRK) reports Tuesday August 4 before market open with analyst consensus at $1.36 diluted EPS (down 36.2% year-over-year from $2.13 in Q2 2025), reflecting post-Keytruda loss-of-exclusivity strategic repositioning and LIPFENDRA (enlicitide, oral macrocyclic peptide PCSK9 inhibitor approved July 16, 2026) launch costs. Eli Lilly (NYSE: LLY) reports Wednesday August 5 before market open with analyst consensus at $20.26 billion revenue and $6.71 EPS. Prediction markets put a 70% probability on another Lilly earnings beat, 96.4% odds Mounjaro (tirzepatide) clears $7.5 billion Q2, 87% odds Zepbound (tirzepatide) tops $4 billion Q2, and Foundayo (orforglipron, oral small-molecule GLP-1) weekly prescriptions near 20,000 as the primary analyst focus number after the April 2026 FDA approval. Novo Nordisk reports Wednesday August 5 H1 2026 results (Novo reports half-year rather than quarterly), with Wegovy pill (oral semaglutide 25/50 mg) Q1 2026 sales of approximately $354 million providing the H1 baseline. The three earnings prints together will frame second-half 2026 obesity market trajectory and the competitive positioning across incretin, macrocyclic peptide, and small-molecule oral GLP-1 franchises.
July 2026 closed as the most consequential peptide-and-obesity policy month in the site's coverage window. Regulatory milestones: the July 1 Medicare GLP-1 Bridge Program launch providing Wegovy (semaglutide), Zepbound KwikPen (tirzepatide), and Foundayo (orforglipron) at $50/month capped copay for approximately 3.8 million eligible Medicare Part D beneficiaries through December 31, 2027; the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session recommending 6 of 7 research peptides for the Section 503A Bulks List (BPC-157 8-6-1, KPV 8-6-1, TB-500 8-6, MOTS-c 7-5-2, Semax 8-5, Epitalon 7-4; Emideltide/DSIP rejected); the July 30 close of the 503B GLP-1 Bulks List exclusion comment period on the April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide; and the Section 232 pharmaceutical tariffs effective date July 31. Product milestones: the July 16 FDA approval of Merck LIPFENDRA (enlicitide) as the first once-daily oral macrocyclic peptide PCSK9 inhibitor (56-59% LDL reduction in CORALreef Phase 3, $315/month launch pricing); the July 7 FDA accelerated approval of Vera Therapeutics TRUTAKNA (atacicept-vymj) for primary IgA nephropathy; the July 17 FDA traditional approval of Novartis Fabhalta (iptacopan) for IgAN; the July 23 Arrowhead Redemplo (plozasiran) Phase 3 SHASTA-3 and SHASTA-4 positive readout (79-81% triglyceride reduction). Industry milestones: the July 19-20 Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide; the July 21 Novo Nordisk lawsuit and July 24 TRO filing against Eli Lilly over GLP-1 advertising; the July 20-23 EMA CHMP recommendation for lerodalcibep (Lyrokaul) monthly PCSK9 fusion protein.
BioPharma Dive published post-PCAC editorial coverage Monday July 27, 2026 framing the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session outcome as advisory endorsement of broader use of six of seven peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) despite the panel's rejection of substantive human efficacy or safety evidence. The editorial frames the vote as a substantive break with the FDA's traditional science-based standard for compounding-substance eligibility and highlights the substantive shift in venture capital and pharmaceutical industry positioning that has followed. Capital is now flowing toward peptide-adjacent companies with documented FDA regulatory engagement (formal drug-development programs seeking NDA or BLA approval), well-defined clinical development strategies (Phase 1-3 registrational programs), and scalable manufacturing infrastructure (state-licensed compounding pharmacies with quality-control documentation, or FDA-registered 503B outsourcing facilities). The commentary contrasts this trajectory with the compounding-pharmacy gray market that has historically dominated peptide distribution (research-chemical suppliers, offshore pharmacies, and clinics operating outside FDA oversight). BioPharma Dive's framing anchors on the July 23-24 PCAC vote as the trigger for the current investment-cycle inflection, and notes that Merck's July 16, 2026 FDA approval of LIPFENDRA (enlicitide, macrocyclic peptide PCSK9 inhibitor) validates the legitimate-drug-development pathway that peptide-industry commentary has framed as an alternative to the compounding-first commercial strategy.
Q2 2026 earnings season for the peptide-and-obesity big three opens next week. Merck reports Tuesday August 4 at 9:00 AM ET with the LIPFENDRA (enlicitide) FDA approval milestone (July 16) roughly one week old at report time; analyst focus areas include the pricing strategy at $10.50 per tablet ($315 per 30-day supply), the pharmacy-benefit distribution model, and initial payer coverage momentum. Eli Lilly reports Wednesday August 5 before market open; analyst focus areas include Foundayo (orforglipron) first-quarter-out US retail sales (Q1 sales were not yet in the books at the last report), Mounjaro and Zepbound growth versus the Wegovy pill franchise, and TRIUMPH-2 and TRIUMPH-3 readouts for retatrutide expected later in 2026. Novo Nordisk reports Thursday August 6; analyst focus areas include the Wegovy pill uptake beyond the 3 million-prescription milestone documented at ADA 2026 (June), the impact of Novo's price cuts in China and India, the Vivani implant partnership announced July 7, and the response to analyst concerns about the January 2027 Wegovy list price reset to $675 (a 50% cut from current levels). The three earnings prints together are expected to frame the second-half 2026 obesity market trajectory and the competitive positioning of the incretin, amylin, and macrocyclic peptide franchises against each other.
Merck LIPFENDRA (enlicitide) commercial-launch details firmed up in the days following Thursday July 16, 2026 FDA approval. List price: $10.50 per tablet, or $315 per 30-day supply before insurance discounts, manufacturer support, or pharmacy benefit adjustments. Distribution channel: standard retail and mail-order pharmacies under the pharmacy benefit, which contrasts with Novartis Leqvio (inclisiran) that runs through the medical benefit due to healthcare-provider subcutaneous administration. Expected pharmacy availability: within weeks of approval. The pharmacy benefit pathway matters for real-world access because it eliminates the buy-and-bill logistics that have slowed injectable PCSK9 adoption (Repatha, Praluent, Leqvio) and puts LIPFENDRA on the same pharmacy shelf as statins and cheaper oral non-statin drugs like Nexletol (bempedoic acid) and Zetia (ezetimibe). The macrocyclic peptide's ability to survive gastrointestinal enzymes is what allows the oral delivery model that unlocks the pharmacy-benefit distribution advantage.
Analyst coverage of Merck's LIPFENDRA (enlicitide) FDA approval (Thursday July 16) crystallized Friday. Financial analysts projected LIPFENDRA can generate more than $2 billion in annual sales after a few years on the market. RBC Capital Markets described the label as 'the cleanest in the PCSK9 class,' noting zero contraindications or hypersensitivity warnings, unlike the currently approved injectable PCSK9 competitors (Amgen Repatha/evolocumab, Regeneron/Sanofi Praluent/alirocumab, and Novartis Leqvio/inclisiran). In supporting Phase 3 data, LIPFENDRA statistically outperformed other oral non-statin drugs (Nexletol/bempedoic acid and Zetia/ezetimibe) in adjunctive hypercholesterolemia populations. LIPFENDRA continues to be evaluated in the large cardiovascular outcomes trial CORALreef Outcomes (NCT06008756), which Merck confirmed has completed enrollment with more than 14,500 participants. It is not yet known whether LIPFENDRA reduces cardiovascular morbidity and mortality; the outcomes trial will address that question. Additional data on the safety profile: in CORALreef Lipids, adverse-reaction frequencies were similar between LIPFENDRA and placebo; in CORALreef HeFH the most common adverse reactions more frequent versus placebo were diarrhea (7% vs. 2%) and dizziness (9% vs. 4%), with discontinuation rates similar to placebo.
The US Food and Drug Administration approved Merck's LIPFENDRA (enlicitide) 20 mg tablets Thursday July 16, 2026 as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). LIPFENDRA is a novel macrocyclic peptide and becomes the first FDA-approved oral PCSK9 inhibitor. In the registrational Phase 3 CORALreef Lipids trial, enlicitide achieved a 56% placebo-adjusted LDL-C reduction; in CORALreef HeFH the reduction was 59%. Every other FDA-approved PCSK9 inhibitor (Amgen's Repatha/evolocumab, Regeneron/Sanofi's Praluent/alirocumab) is delivered by subcutaneous injection every two to four weeks; enlicitide is the first approved as a once-daily oral tablet. Merck priced LIPFENDRA at $315 per month list price, roughly one-third the approximately $700-900/month list prices of the injectable PCSK9 antibodies. The approval extends the macrocyclic peptide platform's clinical validation and opens a new oral chapter for a drug class that had been injectable-only since the first FDA approvals in 2015.